These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9650538)

  • 1. Intravenous and oral propafenone for treatment of tachycardia in infants and children: pharmacokinetics and clinical response.
    Ito S; Gow R; Verjee Z; Giesbrecht E; Dodo H; Freedom R; Tonn GR; Axelson JE; Zalzstein E; Rosenberg HC; Koren G
    J Clin Pharmacol; 1998 Jun; 38(6):496-501. PubMed ID: 9650538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children.
    Li X; Zhang Y; Liu H; Jiang H; Ge H; Zhang Y
    Am J Cardiol; 2017 May; 119(9):1366-1370. PubMed ID: 28283175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propafenone disposition during continuous venovenous hemofiltration.
    Seto W; Trope AE; Gow RM
    Ann Pharmacother; 1999 Sep; 33(9):957-9. PubMed ID: 10492500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the pharmacodynamic effects of intravenous and oral propafenone.
    Haefeli EW; Vozeh S; Ha HR; Follath F
    Clin Pharmacol Ther; 1990 Sep; 48(3):245-54. PubMed ID: 2401123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of oral propafenone in the treatment of arrhythmias in infants and children (European retrospective multicenter study). Working Group on Pediatric Arrhythmias and Electrophysiology of the Association of European Pediatric Cardiologists.
    Janousek J; Paul T
    Am J Cardiol; 1998 May; 81(9):1121-4. PubMed ID: 9605053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with propafenone for cardiac arrhythmias in the young.
    Heusch A; Kramer HH; Krogmann ON; Rammos S; Bourgeous M
    Eur Heart J; 1994 Aug; 15(8):1050-6. PubMed ID: 7527342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of
    Doki K; Shirayama Y; Sekiguchi Y; Aonuma K; Kohda Y; Ieda M; Homma M
    Pharmacogenomics; 2020 Dec; 21(18):1279-1288. PubMed ID: 33203295
    [No Abstract]   [Full Text] [Related]  

  • 8. Propafenone pharmacokinetics and pharmacodynamics in patients with sustained ventricular tachycardia.
    Gillis AM; Wyse DG; Mitchell LB; Duff HJ
    Am J Cardiol; 1996 Sep; 78(5):579-81. PubMed ID: 8806349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HPLC determination of diprafenone and its active metabolite 5-hydroxydiprafenone in human plasma].
    Zhong D; Blume H
    Pharmazie; 1994 Jan; 49(1):38-41. PubMed ID: 8140128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration-effect relations of 5-hydroxypropafenone in normal subjects.
    Haefeli WE; Vozeh S; Ha HR; Taeschner W; Follath F
    Am J Cardiol; 1991 May; 67(11):1022-6. PubMed ID: 2018005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy.
    Capucci A; Boriani G; Marchesini B; Strocchi E; Tomasi L; Balducelli M; Frabetti L; Ambrosioni E; Magnani B
    Cardiovasc Drugs Ther; 1990 Feb; 4(1):281-7. PubMed ID: 2285622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
    Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J
    Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study.
    O'Hara GE; Philippon F; Gilbert M; Champagne J; Michaud V; Charbonneau L; Pruneau G; Hamelin BA; Geelen P; Turgeon J
    J Clin Pharmacol; 2012 Feb; 52(2):171-9. PubMed ID: 21508180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites.
    Fromm MF; Botsch S; Heinkele G; Evers J; Kroemer HK
    Eur J Clin Pharmacol; 1995; 48(3-4):279-83. PubMed ID: 7589055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group.
    Zoble RG; Kirsten EB; Brewington J
    Clin Pharmacol Ther; 1989 May; 45(5):535-41. PubMed ID: 2721109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ECG changes and plasma concentrations of propafenone and its metabolites in a case of severe poisoning.
    Fonck K; Haenebalcke C; Hemeryck A; Belpaire F; Jordaens L; Calle P; Buylaert W
    J Toxicol Clin Toxicol; 1998; 36(3):247-51. PubMed ID: 9656983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias.
    Reimer A; Paul T; Kallfelz HC
    Am J Cardiol; 1991 Sep; 68(8):741-4. PubMed ID: 1892080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiologic, inotropic and antiarrhythmic effects of propafenone, 5-hydroxypropafenone and N-depropylpropafenone.
    Malfatto G; Zaza A; Forster M; Sodowick B; Danilo P; Rosen MR
    J Pharmacol Exp Ther; 1988 Aug; 246(2):419-26. PubMed ID: 3404440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological cardioversion of atrial fibrillation with intravenous and oral propafenone].
    Peciuliene I; Lukoseviciūte A
    Medicina (Kaunas); 2002; 38(12):1212-6. PubMed ID: 12552163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.